Clinical trials data
Paced Visual Serial Addition Test in multiple sclerosis trials: 169 registered studies
Every registered multiple sclerosis study on ClinicalTrials.gov that names the Paced Visual Serial Addition Test in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered multiple sclerosis studies name it in an outcome measure
- 169
- Name it in a primary outcome, 36%
- 61 of 169
Tests named in the same studies
- 1
Symbol Coding66 studies, 33 as a primary outcome
- 2
Verbal Learning29 studies, 13 as a primary outcome
- 3
Verbal Fluency27 studies, 9 as a primary outcome
- 4
Stroop Color-Word Test19 studies, 9 as a primary outcome
- 5
Selective Reminding Task16 studies, 7 as a primary outcome
- 6
Trail Making Test8 studies, 1 as a primary outcome
- 7
Digit Span Test7 studies, 3 as a primary outcome
- 8
Line Angle Matching5 studies, 2 as a primary outcome
- 9
Category Fluency3 studies, 2 as a primary outcome
- 10
Go/No-Go Task3 studies, 0 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 3 | 1 |
| 2003 | 3 | 2 |
| 2004 | 2 | 1 |
| 2005 | 0 | 0 |
| 2006 | 4 | 0 |
| 2007 | 4 | 0 |
| 2008 | 5 | 1 |
| 2009 | 8 | 4 |
| 2010 | 5 | 2 |
| 2011 | 7 | 3 |
| 2012 | 7 | 4 |
| 2013 | 8 | 3 |
| 2014 | 12 | 6 |
| 2015 | 9 | 3 |
| 2016 | 8 | 2 |
| 2017 | 8 | 3 |
| 2018 | 12 | 5 |
| 2019 | 14 | 5 |
| 2020 | 4 | 1 |
| 2021 | 9 | 4 |
| 2022 | 5 | 3 |
| 2023 | 10 | 2 |
| 2024 | 9 | 3 |
| 2025 | 4 | 2 |
| 2026 | 9 | 1 |
Phases and study sizes
By phase
- Early phase 12 studies, 0 as a primary outcome
- Phase 14 studies, 1 as a primary outcome
- Phase 1/214 studies, 4 as a primary outcome
- Phase 221 studies, 7 as a primary outcome
- Phase 2/34 studies, 4 as a primary outcome
- Phase 318 studies, 2 as a primary outcome
- Phase 411 studies, 5 as a primary outcome
- Not applicable71 studies, 27 as a primary outcome
- Observational24 studies, 11 as a primary outcome
Participants per study
- Phase 1/254 median, 38 to 69
- Phase 265 median, 48 to 129
- Phase 3828 median, 338 to 1,055
- Phase 454 median, 23 to 164
- Not applicable45 median, 26 to 99
- Observational97 median, 60 to 196
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Phase 1/2 | 13 | 54 | 38 to 69 |
| Phase 2 | 21 | 65 | 48 to 129 |
| Phase 3 | 18 | 828 | 338 to 1,055 |
| Phase 4 | 11 | 54 | 23 to 164 |
| Not applicable | 70 | 45 | 26 to 99 |
| Observational | 24 | 97 | 60 to 196 |
When multiple sclerosis trials measure it
Latest time point of each outcome
- Within a day19 outcomes, 7 as a primary outcome
- Up to 4 weeks6 outcomes, 2 as a primary outcome
- 1 to 3 months36 outcomes, 14 as a primary outcome
- 3 to 6 months22 outcomes, 7 as a primary outcome
- 6 to 12 months30 outcomes, 11 as a primary outcome
- 1 to 2 years24 outcomes, 7 as a primary outcome
- Over 2 years17 outcomes, 6 as a primary outcome
- No duration given15 outcomes, 7 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
154 of the 169 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting18 studies, 3 as a primary outcome
- Not yet recruiting8 studies, 2 as a primary outcome
- Active, not recruiting3 studies, 2 as a primary outcome
- Completed105 studies, 40 as a primary outcome
- Stopped early15 studies, 3 as a primary outcome
- Status unknown20 studies, 11 as a primary outcome
What they test
- Behavioral31 studies, 10 as a primary outcome
- Drug58 studies, 21 as a primary outcome
- Device21 studies, 9 as a primary outcome
- Dietary supplement5 studies, 1 as a primary outcome
- Procedure8 studies, 3 as a primary outcome
- Diagnostic test3 studies, 0 as a primary outcome
- Biological16 studies, 2 as a primary outcome
- Combination product2 studies, 0 as a primary outcome
- Other46 studies, 16 as a primary outcome
- None given10 studies, 6 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States52 studies, 19 as a primary outcome
- Italy34 studies, 12 as a primary outcome
- France30 studies, 5 as a primary outcome
- Canada23 studies, 7 as a primary outcome
- Germany23 studies, 3 as a primary outcome
- United Kingdom21 studies, 3 as a primary outcome
- Belgium19 studies, 6 as a primary outcome
- Spain19 studies, 6 as a primary outcome
- Czechia18 studies, 5 as a primary outcome
- Poland18 studies, 3 as a primary outcome
- Türkiye18 studies, 6 as a primary outcome
- Israel14 studies, 4 as a primary outcome
60 countries in all. A study with sites in several counts in each; 12 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed multiple sclerosis studies that name the Paced Visual Serial Addition Test: 60 of 105, 57%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed multiple sclerosis studies that name the Paced Visual Serial Addition Test | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 22, 21% | 776, 10% |
| Results on ClinicalTrials.gov only | 14, 13% | 1,139, 14% |
| A results paper only | 24, 23% | 1,711, 22% |
| Neither | 45, 43% | 4,327, 54% |
The 169 studies
169 studies match. 61 name the Paced Visual Serial Addition Test in a primary outcome. Median size 67 participants. Median time to the primary outcome: 6 months.
Loading 169 studies; the filters turn on when they arrive.
2026 is partly planned starts.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 3 | 1 |
| 2003 | 3 | 2 |
| 2004 | 2 | 1 |
| 2005 | 0 | 0 |
| 2006 | 4 | 0 |
| 2007 | 4 | 0 |
| 2008 | 5 | 1 |
| 2009 | 8 | 4 |
| 2010 | 5 | 2 |
| 2011 | 7 | 3 |
| 2012 | 7 | 4 |
| 2013 | 8 | 3 |
| 2014 | 12 | 6 |
| 2015 | 9 | 3 |
| 2016 | 8 | 2 |
| 2017 | 8 | 3 |
| 2018 | 12 | 5 |
| 2019 | 14 | 5 |
| 2020 | 4 | 1 |
| 2021 | 9 | 4 |
| 2022 | 5 | 3 |
| 2023 | 10 | 2 |
| 2024 | 9 | 3 |
| 2025 | 4 | 2 |
| 2026 | 9 | 1 |
Library tests named most
Conditions
Phases
Participants
Lead sponsor: industry 41, NIH 1, other 127. Interventional 145, observational 24.
As a primary outcomeSecondary or other outcomeThe Paced Visual Serial Addition Test
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07842302 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis, Pain and fatigue | Participants80 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07827716 | Start2026 | PhasePhase 2 | ConditionsMultiple sclerosis | Participants100 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07734675 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants130 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07640100 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants45 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07571304 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants22 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07546721 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants12 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07374237 | Start2025 | PhaseObservational | ConditionsMultiple sclerosis, Sleep and sleep disorders, Pain and fatigue | Participants102 | Lead sponsorOther | StatusCompleted | Library tests named |
| NCT07273604 | Start2015 | PhaseNot applicable | ConditionsMultiple sclerosis, Depression and bipolar disorder, Anxiety, PTSD and OCD, Pain and fatigue | Participants148 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07257900 | Start2025 | PhaseNot applicable | ConditionsMultiple sclerosis, Aging, frailty and exercise | Participants30 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07189325 | Start2026 | PhasePhase 3 | ConditionsMultiple sclerosis | Participants250 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07114809 | Start2024 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants80 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07058896 | Start2024 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants18 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07058870 | Start2024 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants18 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06964581 | Start2023 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06841068 | Start2026 | PhasePhase 1/2 | ConditionsMultiple sclerosis | ParticipantsNot given | Lead sponsorOther | StatusStopped early | Library tests named
|
| NCT06820125 | Start2023 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants48 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06800144 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants45 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06715436 | Start2024 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants111 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06676618 | Start2025 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06672770 | Start2024 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants63 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT06629155 | Start2025 | PhaseObservational | ConditionsMultiple sclerosis | Participants50 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT06586177 | Start2021 | PhaseObservational | ConditionsMultiple sclerosis | Participants100 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06501950 | Start2024 | PhaseObservational | ConditionsMultiple sclerosis | Participants77 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06485115 | Start2024 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants78 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT06461481 | Start2024 | PhaseObservational | ConditionsMultiple sclerosis | Participants150 | Lead sponsorOther | StatusRecruiting | Library tests named
|
Questions, answered from the data
How many multiple sclerosis trials use the Paced Visual Serial Addition Test?
169 registered multiple sclerosis studies on ClinicalTrials.gov name it in an outcome measure, 61 of them in a primary outcome: 28% of the condition's 612 studies with a cognitive outcome, against 2% of all of them. It is the 2nd most named test in multiple sclerosis trials.
Which tests do multiple sclerosis trials use with the Paced Visual Serial Addition Test?
Symbol Coding (66 studies), Verbal Learning (29 studies) and Verbal Fluency (27 studies).
How many participants do phase 2 multiple sclerosis trials that use the Paced Visual Serial Addition Test enroll?
Half of the phase 2 studies that name it enroll 65 participants or fewer, and the middle half enroll 48 to 129. 21 of them give a size.
When do multiple sclerosis trials measure the Paced Visual Serial Addition Test?
Half of the primary outcomes that name the Paced Visual Serial Addition Test are measured within 6 months of the start, and the middle half from 8 weeks to 12 months. 54 primary outcomes give a duration.
How many completed multiple sclerosis trials that use the Paced Visual Serial Addition Test have reported results?
60 of the 105 completed studies that name it, 57%, have reported results: 36 posted them on ClinicalTrials.gov, 46 have a results paper linked to the registry record, and 22 did both. The other 45 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
Run the Paced Visual Serial Addition Test in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.